297 related articles for article (PubMed ID: 26646452)
1. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.
Kashyap MK; Kumar D; Jones H; Amaya-Chanaga CI; Choi MY; Melo-Cardenas J; Ale-Ali A; Kuhne MR; Sabbatini P; Cohen LJ; Shelat SG; Rassenti LZ; Kipps TJ; Cardarelli PM; Castro JE
Oncotarget; 2016 Jan; 7(3):2809-22. PubMed ID: 26646452
[TBL] [Abstract][Full Text] [Related]
2. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
[TBL] [Abstract][Full Text] [Related]
3. AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments.
Stamatopoulos B; Meuleman N; De Bruyn C; Pieters K; Mineur P; Le Roy C; Saint-Georges S; Varin-Blank N; Cymbalista F; Bron D; Lagneaux L
Haematologica; 2012 Apr; 97(4):608-15. PubMed ID: 22058221
[TBL] [Abstract][Full Text] [Related]
4. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
Burger M; Hartmann T; Krome M; Rawluk J; Tamamura H; Fujii N; Kipps TJ; Burger JA
Blood; 2005 Sep; 106(5):1824-30. PubMed ID: 15905192
[TBL] [Abstract][Full Text] [Related]
5. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies.
Kuhne MR; Mulvey T; Belanger B; Chen S; Pan C; Chong C; Cao F; Niekro W; Kempe T; Henning KA; Cohen LJ; Korman AJ; Cardarelli PM
Clin Cancer Res; 2013 Jan; 19(2):357-66. PubMed ID: 23213054
[TBL] [Abstract][Full Text] [Related]
6. Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Han TT; Fan L; Li JY; Xu W
Cancer Biol Ther; 2014 Jan; 15(1):3-9. PubMed ID: 24149438
[TBL] [Abstract][Full Text] [Related]
7. Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis.
O'Hayre M; Salanga CL; Kipps TJ; Messmer D; Dorrestein PC; Handel TM
PLoS One; 2010 Jul; 5(7):e11716. PubMed ID: 20661426
[TBL] [Abstract][Full Text] [Related]
8. CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy.
Domanska UM; Timmer-Bosscha H; Nagengast WB; Oude Munnink TH; Kruizinga RC; Ananias HJ; Kliphuis NM; Huls G; De Vries EG; de Jong IJ; Walenkamp AM
Neoplasia; 2012 Aug; 14(8):709-18. PubMed ID: 22952424
[TBL] [Abstract][Full Text] [Related]
9. Role of CXCL12-CXCR4 axis in ovarian cancer metastasis and CXCL12-CXCR4 blockade with AMD3100 suppresses tumor cell migration and invasion in vitro.
Liu Y; Ren CC; Yang L; Xu YM; Chen YN
J Cell Physiol; 2019 Apr; 234(4):3897-3909. PubMed ID: 30191987
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies.
Peng SB; Zhang X; Paul D; Kays LM; Ye M; Vaillancourt P; Dowless M; Stancato LF; Stewart J; Uhlik MT; Long H; Chu S; Obungu VH
PLoS One; 2016; 11(3):e0150585. PubMed ID: 26954567
[TBL] [Abstract][Full Text] [Related]
11. Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.
Messmer D; Fecteau JF; O'Hayre M; Bharati IS; Handel TM; Kipps TJ
Blood; 2011 Jan; 117(3):882-9. PubMed ID: 21079155
[TBL] [Abstract][Full Text] [Related]
12. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
[TBL] [Abstract][Full Text] [Related]
13. Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies.
ten Hacken E; Burger JA
Pharmacol Ther; 2014 Dec; 144(3):338-48. PubMed ID: 25050922
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1).
Möhle R; Failenschmid C; Bautz F; Kanz L
Leukemia; 1999 Dec; 13(12):1954-9. PubMed ID: 10602415
[TBL] [Abstract][Full Text] [Related]
15. CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.
Ganghammer S; Hutterer E; Hinterseer E; Brachtl G; Asslaber D; Krenn PW; Girbl T; Berghammer P; Geisberger R; Egle A; Zucchetto A; Kruschinski A; Gattei V; Chigaev A; Greil R; Hartmann TN
Oncotarget; 2015 May; 6(14):12048-60. PubMed ID: 25895128
[TBL] [Abstract][Full Text] [Related]
16. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach.
Niedermeier M; Hennessy BT; Knight ZA; Henneberg M; Hu J; Kurtova AV; Wierda WG; Keating MJ; Shokat KM; Burger JA
Blood; 2009 May; 113(22):5549-57. PubMed ID: 19318683
[TBL] [Abstract][Full Text] [Related]
17. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.
Buchner M; Baer C; Prinz G; Dierks C; Burger M; Zenz T; Stilgenbauer S; Jumaa H; Veelken H; Zirlik K
Blood; 2010 Jun; 115(22):4497-506. PubMed ID: 20335218
[TBL] [Abstract][Full Text] [Related]
18. Dasatinib inhibits CXCR4 signaling in chronic lymphocytic leukaemia cells and impairs migration towards CXCL12.
McCaig AM; Cosimo E; Leach MT; Michie AM
PLoS One; 2012; 7(11):e48929. PubMed ID: 23133664
[TBL] [Abstract][Full Text] [Related]
19. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells.
Stamatopoulos B; Meuleman N; De Bruyn C; Delforge A; Bron D; Lagneaux L
Haematologica; 2010 Jul; 95(7):1136-43. PubMed ID: 20145270
[TBL] [Abstract][Full Text] [Related]
20. Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia.
Opel D; Schnaiter A; Dodier D; Jovanovic M; Gerhardinger A; Idler I; Mertens D; Bullinger L; Stilgenbauer S; Fulda S
Int J Cancer; 2015 Dec; 137(12):2959-70. PubMed ID: 26096065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
